Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Natera is a established genetic diagnostic and research company with strong financials and growth potential in the genomic profiling market, specifically in prenatal and cancer testing. Despite facing competition and risks in expanding internationally, Natera has shown success and potential in securing contracts and launching new tests. They also have a focus on changing disease management and revenue growth in non-covered indications, with promising results in organ transplant monitoring and improving outcomes for certain cancer patients.

Bears say

Natera is a leader in the highly competitive diagnostic and research industry, but faces risks such as potential regulatory hurdles and reliance on lab partnerships. The company's strong competition in the prenatal and oncology markets may make it difficult to secure market share. Additionally, factors such as seasonality, changing reimbursement rates, and reliance on Medicaid may negatively impact Natera's financial performance in the future.

Natera (NTRA) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 14 analysts, Natera (NTRA) has a Buy consensus rating as of Apr 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $259.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $259.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.